PGC1α drives NAD biosynthesis linking oxidative metabolism to renal protection

Nature. 2016 Mar 24;531(7595):528-32. doi: 10.1038/nature17184. Epub 2016 Mar 16.

Abstract

The energetic burden of continuously concentrating solutes against gradients along the tubule may render the kidney especially vulnerable to ischaemia. Acute kidney injury (AKI) affects 3% of all hospitalized patients. Here we show that the mitochondrial biogenesis regulator, PGC1α, is a pivotal determinant of renal recovery from injury by regulating nicotinamide adenine dinucleotide (NAD) biosynthesis. Following renal ischaemia, Pgc1α(-/-) (also known as Ppargc1a(-/-)) mice develop local deficiency of the NAD precursor niacinamide (NAM, also known as nicotinamide), marked fat accumulation, and failure to re-establish normal function. Notably, exogenous NAM improves local NAD levels, fat accumulation, and renal function in post-ischaemic Pgc1α(-/-) mice. Inducible tubular transgenic mice (iNephPGC1α) recapitulate the effects of NAM supplementation, including more local NAD and less fat accumulation with better renal function after ischaemia. PGC1α coordinately upregulates the enzymes that synthesize NAD de novo from amino acids whereas PGC1α deficiency or AKI attenuates the de novo pathway. NAM enhances NAD via the enzyme NAMPT and augments production of the fat breakdown product β-hydroxybutyrate, leading to increased production of prostaglandin PGE2 (ref. 5), a secreted autacoid that maintains renal function. NAM treatment reverses established ischaemic AKI and also prevented AKI in an unrelated toxic model. Inhibition of β-hydroxybutyrate signalling or prostaglandin production similarly abolishes PGC1α-dependent renoprotection. Given the importance of mitochondrial health in ageing and the function of metabolically active organs, the results implicate NAM and NAD as key effectors for achieving PGC1α-dependent stress resistance.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • 3-Hydroxybutyric Acid / metabolism
  • Acute Kidney Injury / drug therapy
  • Acute Kidney Injury / metabolism*
  • Adipose Tissue / drug effects
  • Adipose Tissue / metabolism
  • Amino Acids / metabolism
  • Animals
  • Cytokines / metabolism
  • Dinoprostone / biosynthesis
  • Dinoprostone / metabolism
  • Humans
  • Ischemia / drug therapy
  • Ischemia / metabolism
  • Kidney / drug effects
  • Kidney / metabolism*
  • Kidney / physiology
  • Kidney / physiopathology
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mitochondria / metabolism
  • NAD / biosynthesis*
  • Niacinamide / deficiency
  • Niacinamide / pharmacology
  • Niacinamide / therapeutic use
  • Nicotinamide Phosphoribosyltransferase / metabolism
  • Oxidation-Reduction
  • Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha
  • Signal Transduction / drug effects
  • Stress, Physiological
  • Transcription Factors / deficiency
  • Transcription Factors / metabolism*

Substances

  • Amino Acids
  • Cytokines
  • Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha
  • Ppargc1a protein, mouse
  • Transcription Factors
  • NAD
  • Niacinamide
  • Nicotinamide Phosphoribosyltransferase
  • nicotinamide phosphoribosyltransferase, mouse
  • Dinoprostone
  • 3-Hydroxybutyric Acid